Drugs & Pharmaceuticals

Over the past few months I've been arguing that remdesivir, the only approved drug for SARS-2 infection, was never going to make a meaningful impact on COVID because it is an IV-only drug, meaning that it will only be administered to ver

I want to return to my favorite topic, antibiotics, viewed through the lens of the COVID-19 pandemic. Of course, as is probably true for all of us, my perspective is colored by my own history and experience.

The endless daily reports of possible vaccines and potential drugs to treat coronavirus all mention the need for clinical trials before the drug or a vaccine can be approved for use, but without making it clear what the trial involve.

Sometimes science makes sense.

Is sticking your finger down your throat a pleasant experience? (Sorry, bulimics excluded) How about sticking it down there and leaving it for three weeks? This is not a gag (sorry).

One of the many horrors that drug discovery chemists constantly wrestle with is called pharmacokinetics (PK) – the science of what the body does to a drug (1).

Does it make any sense to use an antibiotic like this?

Pricing a new drug is not an easy task, Gilead who is producing remdesivir is no stranger to pricing controversy, the release of Solvaldi, their drug to cure Hepatitis C, had a list price of $84,000 for a full treatment course.

Those who cannot remember the past are condemned to repeat it. (George Santayana). Never let a good crisis go to waste. (Churchill? Emanuel?).

What a letdown.